Recent Updates
Recently added Catalysts
VNRX Neutral Sentiment

Video: Transcription Factor DNA in Plasma New Data Revealed

Wednesday, March 25, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The article discusses new data regarding the prognostic value of the Nu.Q® cancer test and its relevance in assessing transcription factor DNA in plasma. It highlights related research on cytokine-induced chromatin accessibility in neutrophils and its connection to sepsis. The content suggests ongoing developments in cancer diagnostics and related fields.
Price reaction · baseline $4.294 (2026-03-25T15:32:00.000Z) · hit during market hours · 3 other VNRX headline(s) in the window, move may be shared
day 0 close
-10.9%
day 1
-10.1%
day 3 · peak
-11.5%

Market Sentiment Analysis

Full Press Release Details

Related Articles

• Press Releases Data Showing the Prognostic Value of its Nu.Q® Cancer Test
• Poster & Publications Cytokine-induced chromatin accessibility in whole blood neutrophils links to sepsis transcriptional states

Data Showing the Prognostic Value of its Nu.Q® Cancer Test

Cytokine-induced chromatin accessibility in whole blood neutrophils links to sepsis transcriptional states

• Share
• Tweet
• Share on Facebook
• Share

Subscribe for Volition product updates .

Or, click here for Investor Updates and press releases .

" * " indicates required fields
ShareAdd on Google
Tags: VNRX Viatris Investor Conferences Healthcare Nu.Q® cancer test plasma diagnostics sepsis chromatin accessibility
Last updated: Mar 25, 2026

Biotech snapshot

Cash runway
$3M liquidity · $2M/mo burn
~1 mo
High dilution risk